EMA recommends marketing approval for Amgen Europe’s Tepezza to treat adults with moderate to severe thyroid eye disease: Amsterdam, The Netherlands Monday, April 28, 2025, 11:0 ...

Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.

5 Fig 1. Timeline of FDA and EMA approvals for bispecific antibodies. The image shows key regulatory approvals of bsAbs from 2014 to 2024. 1L, first line treatment; B-ALL, B-cell ALL; DLBCL, diffuse ...

Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan (University of California, San Diego), Julio Rojas (UCSF) and ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.

The European Commission (EC) has at last granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...